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Abstract
Neuropeptide S (NPS) increasingly emerges as a potential novel treatment option for anxiety diseases like panic and
posttraumatic stress disorder. However, the neural underpinnings of its anxiolytic action are still not clearly understood.
Recently, we reported that neurons of the ventral hippocampus (VH) take up intranasally administered fluorophore-
conjugated NPS and, moreover, that application of NPS to mouse brain slices affects neurotransmission and plasticity at
hippocampal CA3-CA1 synapses. Although these previous findings define the VH as a novel NPS target structure, they leave
open whether this brain region is directly involved in NPS-mediated anxiolysis and how NPS impacts on neuronal activity
propagation in the VH. Here, we fill this knowledge gap by demonstrating, first, that microinjections of NPS into the ventral
CA1 region are sufficient to reduce anxiety-like behavior of C57BL/6N mice and, second, that NPS, via the NPS receptor,
rapidly weakens evoked neuronal activity flow from the dentate gyrus to area CA1 in vitro. Additionally, we show that
intranasally applied NPS alters neurotransmission and plasticity at CA3-CA1 synapses in the same way as NPS administered
to hippocampal slices. Thus, our study provides, for the first time, strong experimental evidence for a direct involvement of
the VH in NPS-induced anxiolysis and furthermore presents a novel mechanism of NPS action.
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Introduction
Neuropeptide systems receive increasing attention as potential
novel pharmacotherapeutic options for the treatment of patho-
logical anxiety, which is a core symptom of anxiety diseases like
panic and posttraumatic stress disorder (PTSD) [1], [2]. In this
context, the neuropeptide S (NPS) system is of special interest as it
has been well established that NPS exerts pronounced anxiolytic
effects in rodents both after central [3], [4] and after intranasal
administration [5], [6]. However, the mechanisms underlying
NPS-elicited anxiolytic effects still remain elusive. We recently
demonstrated that intranasally applied fluorescent Cy3-NPS is
taken up into neurons not only in various mouse brain regions
previously known as NPS receptor (NPSR) expression sites like the
amygdala and the hypothalamic nuclei [7], [8], but interestingly
also in the ventral hippocampus (VH) [5]. The VH, which has
been described as a player in the anxiety network both in rodents
and humans [9]–[11], has not been associated with NPS actions to
date, although this limbic region is well known as a target of other
neuropeptides like oxytocin [12], arginine vasopressin [13], NPY
and cholecystokinin (CCK) [14]. Interestingly, CCK8 microinfu-
sions into the VH were reported to induce anxiety-like behavior in
rats [15]. However, reports on the mechanisms underlying VH-
mediated anxiolysis are scarce [9], whereas the role of the
amygdala and the prefrontal cortex (PFC) in anxiety regulation
and anxiety disorders has been widely studied and confirmed
[16]–[19]. In addition to identifying NPS target neurons in the
VH, we lately demonstrated that bath application of NPS to
mouse brain slices decreases paired-pulse facilitation and long-
term potentiation (LTP) at CA3-CA1 synapses. These NPS effects
were inhibited by the specific NPSR antagonist (R)-SHA 68 [5].
Analyses of NPSR knockout mice revealed NPSR to be the sole
mediator of NPS effects [20], [21]. Our previous findings leave the
following questions open: First, whether intranasally applied NPS
leads to the same effects on neurotransmission and plasticity at
CA3-CA1 synapses in awake mice as NPS bath application to
murine hippocampal slices; second, whether the VH is directly
involved in NPS-mediated anxiolysis; and third, how NPS
influences neuronal activity flow within the hippocampus. Here,
we fill these knowledge gaps, first, by analyzing potential changes
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in input-output relationships, paired-pulse facilitation and LTP at
CA3-CA1 synapses in brain slices prepared from C57BL/6N mice
previously treated intranasally with NPS; second, by testing
whether microinjections of NPS directly into the ventral CA1
region (vCA1) are sufficient to reduce anxiety-like behavior in
C57BL/6N mice mice; and third, by investigating whether and
how NPS influences evoked neuronal activity propagations from
the dentate gyrus (DG) to the CA1 subfield.
Materials and Methods
Animals
All experiments were performed in adult (10- to 12-week-old)
male mice. For behavioral experiments, C57BL/6N mice were
purchased from Charles River Germany GmbH (Sulzfeld,
Germany). For all other experiments, we used C57BL/6N animals
bred in the animal facility of the Max Planck Institute of
Biochemistry (Martinsried, Germany). All mice were housed
individually for at least 6 days before the start of the experiments,
on a 12 h light/dark cycle with food and water ad libitum. All
procedures were approved by the Government of Upper Bavaria
and were in accordance with European Union Directive 86/609/
EEC.
Chemicals
Cy3-NPS was purchased from Phoenix Pharmaceuticals
(Karlsruhe, Germany) and rat NPS from Bachem (Bubendorf,
Switzerland). Both were dissolved in artificial cerebrospinal fluid
(ACSF, for composition see below) to the desired final concentra-
tion. DAPI, Di-4-ANEPPS and all salts for the ACSF were
purchased from Sigma-Aldrich (Taufkirchen, Germany). A
20.8 mM stock solution of Di-4-ANEPPS was prepared in
dimethylsulfoxide (DMSO). The active enantiomer of the specific
NPSR antagonist SHA 68, (R)-SHA 68 [22], [23], was a generous
gift from A. Sailer (Novartis, Basel, Switzerland). (R)-SHA 68 was
dissolved in DMSO and diluted for use in ACSF at a final
concentration of 10 mM (,0.1% DMSO).
Surgery
Surgery was performed as previously described [5]. Briefly, 23
gauge guide cannulas were implanted in the CA1 region of the
VH at the following coordinates: 3.1 mm posterior and 63 mm
lateral from bregma, and 2 mm ventral from the skull surface [24].
For behavioral experiments, animals were implanted bilaterally;
for Cy3-NPS injections, implantation was performed unilaterally.
The animals were allowed to recover for at least 6 days before the
behavioral experiments.
Administration of Cy3-NPS and brain section processing
Cy3-NPS was administered unilaterally at a concentration of
0.07 nmol in a volume of 0.7 ml ACSF at the following
coordinates: 3.1 mm posterior and 63 mm lateral from bregma,
and 4.5 mm ventral from the skull surface [24]. Mice were
sacrificed 30 min after application. Brains were removed and post-
fixed in 4% paraformaldehyde overnight at 4uC, then shock-
frozen in methylbutane and stored at 280uC. 40 mm cryosections
were obtained and processed as previously described [5]. Images
were acquired with a confocal microscope (Olympus IX81,
software: FluoView FV1000 2.1.2.5).
Behavioral experiments
Mice were injected bilaterally either with 0.1 nmol NPS in
0.5 ml ACSF per side or with 0.5 ml of ACSF per side at the same
coordinates as used for the Cy3-NPS injections (see above). 30 min
after injection, three behavioral assays (open field, dark-light test,
and elevated plus-maze (EPM)) were performed sequentially in the
order mentioned. Each test lasted 5 min, with a 5 min break in
between, as described previously [5]. Animal behavior was
videotaped and relevant parameters were analyzed using the
tracking software ANY-maze version 4.30 (Stoelting, Wood Dale,
IL, USA) [25]. Mice were sacrificed 24 h after completion of the
behavioral assays and the locations of the guide cannulas and
injection sites were checked in histological cryosections of 40 mm
counterstained with DAPI. Mice with deviating injection sites were
excluded from further analysis.
Intranasal administration of NPS
was performed as previously described [5]. Briefly, alert mice,
habituated to handling, were restrained manually during the
administration procedure in a supine position with the head
immobile at an angle of approximately 45u to the body (Figure S1).
7 ml of NPS (7 nmol) or ACSF alone were pipetted alternatingly to
each nostril without touching the nasal mucosa; after 5 min, the
procedure was repeated. Mice were then allowed to rest for 2 h
before slice preparation.
Electrophysiology
Field excitatory postsynaptic potential (fEPSP) recordings in
horizontal brain slices (350 mm-thick) containing the VH were
performed as previously described [26]. Only the first two slices
from the ventral surface of the brain in which the CA1 region was
clearly visible were used for the measurements. Hippocampal slices
were continuously perfused (4–5 ml/min flow rate) at room
temperature (23–25uC) in a submerged chamber with carboge-
nated (95% O2/5% CO2) ACSF containing (in mM): NaCl, 125;
KCl, 2.5; NaH2PO4, 1.25; NaHCO3, 25; MgCl2, 1; CaCl2, 2; and
glucose, 25 (pH 7.4). Square pulse electrical stimuli (0.066 Hz,
50 ms) were delivered to the stratum radiatum of the CA1 subfield
and evoked fEPSPs were recorded. In all experiments (to allow
comparison between the NPS- and vehicle-treated animals) the
stimulation intensity was set to the half maximum intensity at
which population spikes appeared. The paired-pulse ratio was
calculated as fEPSP2 amplitude/fEPSP1 amplitude. LTP was
induced by high-frequency stimulation (HFS, 100 stimuli at
100 Hz).
Voltage-sensitive dye imaging (VSDI)
According to Maggio and Segal [27] and Fanselow and Dong
[28], VSDI experiments were conducted in the VH. Horizontal
brain slices (350 mm-thick) were prepared as previously described
[29]–[31]. For staining, slices were kept for 15 min in carboge-
nated ACSF containing the voltage-sensitive dye Di-4-ANEPPS
(7.5 mg/ml, ,0.1% DMSO), before being stored for at least
30 min in normal ACSF. VSDI and data analysis were performed
using the MiCAM02 hard- and software package (BrainVision,
Tokyo, Japan). The tandem-lens fluorescence microscope was
equipped with the MiCAM02-HR camera and the 26 and 16
lens at the objective and condensing side, respectively (for further
technical details see http://www.scimedia.com). Acquisition
settings were: 88660 pixels frame size, 36.4640.0 mm pixel size,
and 2.2 ms sampling time. To reduce noise, four acquisitions
subsequently recorded at intervals of 5 s were averaged. Neuronal
activity was evoked by square pulse electrical stimuli (200 ms, 15–
20 V) delivered to the DG granule cell layer via a custom-made
monopolar tungsten electrode (Teflon-insulated to the tip of
50 mm diameter). From recorded signals, the fractional change in
fluorescence (DF/F) was calculated. For all quantifications, DF/F
values were spatially and temporally smoothed using a 36363
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average filter. VSDI signals presented in images were smoothed
with a 56563 average filter. Pixelation of images was reduced by
the interpolation function of the MiCAM02 software. For analysis
of neuronal population activity in hippocampal subregions, three
standardized circular regions of interest (ROIs) were manually set
according to anatomical landmarks. The first ROI (r=3 pixels),
termed ‘Hilus’, was placed centrally into the hilus of the DG,
between the tip of the stimulation electrode and the proximal end
of the CA stratum pyramidale. The second ROI ‘CA3’ (r=6
pixels) was positioned into the CA3 region near the DG, but not
overlapping with it. The third ROI ‘CA1’ (r=6 pixels) was placed
into the CA1 subfield with a distance of approximately 400 mm
from the visually identified distal end of the CA3 region. Both the
‘CA3’ and the ‘CA1’ ROI spanned the stratum oriens, stratum
pyramidale, and stratum radiatum (lucidum). The average of
smoothed DF/F values within a particular ROI served as final
measure of neuronal population activity.
Statistics
Statistical analysis was performed using Sigma Stat 3.5 and
GraphPad Prism 5.03. Statistical significance was assessed by
means of the two-tailed unpaired Student’s t-test, except for the
VSDI experiments for which the two-tailed paired Student’s t-test
was used. Data are given as mean 6 SEM. In all graphs, p values
are depicted as follows: *p,0.05, **p,0.01, ***p,0.001.
Results
Intranasally applied NPS impacts on basal glutamatergic
neurotransmission and short- and long-term plasticity at
CA3-CA1 synapses of the VH
First, to corroborate our previous findings on the role of the VH
in the effects of intranasally administered NPS, we analyzed
whether intranasally applied NPS, like bath-applied NPS (1 mM)
[5], also impacts on paired-pulse facilitation and LTP at CA3-CA1
synapses. To this end, we performed field potential recordings in
VH slices obtained from C57BL/6N mice which had been
previously treated intranasally with 14 nmol NPS or vehicle. We
decided to conduct the electrophysiological measurements 4 h
after treatment since we determined earlier that intranasally
applied NPS leads to a statistically significant anxiolytic effect 4 h
after application [5]. In our previous study, we demonstrate that
the specific NPSR antagonist (R)-SHA 68 prevents NPS-mediated
modulation of basal glutamatergic neurotransmission and plastic-
ity.
As shown in Figure 1, intranasal administration of NPS to
C57BL/6N mice led to weakening of both paired-pulse facilitation
and LTP at CA3-CA1 synapses (values for LTP: 3965.23% for
vehicle-treated vs. 2262.62% for NPS-treated animals, p=0.009).
Analysis of input-output relationships at these synapses showed
that intranasal NPS application induced a shift of input-output
curves towards bigger fEPSP amplitudes (Figure 1). Taken
together, both bath-applied [5] and intranasally applied NPS
influence basal glutamatergic neurotransmission and plasticity at
CA3-CA1 synapses in the same direction.
Figure 1. Intranasally applied NPS impacts on basal glutamatergic neurotransmission and plasticity at CA3-CA1 synapses of the VH
in C57BL/6N mice. A, Intranasal NPS administration caused a shift of the input-output curve towards bigger fEPSP amplitudes (Vehicle: open
squares: n = 12 slices from 7 mice; NPS: closed squares: n = 11 slices from 5 mice). B, Intranasally applied NPS reduced paired-pulse facilitation at
interstimulus intervals of 25, 50, 100, and 200 ms (Vehicle: open squares: n = 14 slices from 7 mice; NPS: closed squares: n = 11 slices from 5 mice). C,
Intranasal NPS application decreased the magnitude of LTP at CA3-CA1 synapses induced by high-frequency stimulation (HFS) (Vehicle: open squares:
n = 10 slices from 5 mice, LTP magnitude for minutes 71–80= 3965%; NPS: closed squares: n = 10 slices from 5 mice, LTP magnitude for minutes 71–
80 = 2263%; p = 0.009, t = 2.944, df = 18).
doi:10.1371/journal.pone.0060219.g001
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Microinjections of NPS into the VH reduce anxiety-like
behavior
Next, we wanted to find out whether the VH is directly involved
in NPS-mediated anxiolysis. Before examining whether microin-
jections of NPS into the CA1 subfield of the VH modulate anxiety
in C57BL/6N mice, we analyzed the distribution of the injected
NPS using a fluorescent conjugate, i.e. Cy3-NPS. 30 min after
injection, Cy3-NPS remained locally restricted to the VH and
accumulated in single neurons of the hippocampal pyramidal,
radiate, and oriens layers (red fluorescence in Figure 2A). After
intrahippocampal injection, we never observed an uptake of Cy3-
NPS in nuclei of the amygdala (Figure 2B).
Thereupon, we investigated whether injections of unlabeled
NPS into the vCA1 region produce similar anxiolytic effects as
seen after intra-amygdalar [7] and intracerebroventricular (ICV)
injections [3], [4], [32] as well as after intranasal administration
[5], [6]. To this end, we employed standardized paradigms to
study anxiety-related behavior 30 min after injection, as this time-
point has been repeatedly shown to be optimal for measuring
behavioral changes after intracerebral NPS injection [3], [7].
Anxiety- and locomotion-related parameters were examined in
both the dark-light test and the EPM. Basal locomotion was
determined by means of the open field test. Intra-vCA1-injected
NPS did not significantly alter locomotion in any of the three tests
(Figure 3B–D). However, most interestingly, NPS treatment
elicited a significant anxiolytic effect on the EPM, as evident from
an increase in the percentage of time spent on the open arms
(Figure 3D, p=0.042). These results are in accordance with our
previous findings demonstrating that intranasally applied NPS
causes the strongest anxiolytic effect on the EPM [5].
NPS weakens neuronal activity flow from the DG to area
CA1
Finally, we analyzed the influence of NPS on neuronal activity
flow in the VH. Field potential recordings, as employed to
generate the results shown in Figure 1, are a valuable tool to
uncover changes in basal synaptic transmission and plasticity, but
they are not suited to unveil alterations in neuronal network
dynamics, which might be a closer neurophysiological correlate of
behavior [29], [33], [34]. We recently established a high-speed
voltage-sensitive dye imaging (VSDI) assay in mouse brain slices
enabling the investigation of evoked neuronal activity propaga-
tions from the DG to area CA1 [29], [30], which is of high
physiological relevance since the DG represents the major input
region and area CA1 an important output subfield of the
hippocampus [28]. We analyzed stimulus-evoked fast, depolariza-
tion-mediated imaging signals (‘FDSs’), which reflect neuronal
action potentials and EPSPs [29]–[31], [33].
Bath application of NPS (1 mM) to VH slices rapidly weakened
the stimulus-evoked activity flow from the DG to the CA1 subfield
(Figure 4A, B). This effect was completely abolished by the specific
NPSR antagonist (R)-SHA 68 (10 mM) (Figure 4B, C), proving
that the effects observed are mediated by the NPS/NPSR
complex. NPS reduced the amplitude of FDSs in the dentate
hilus, the CA3 region, and area CA1, indicating that NPS effects
on neuronal activity in the VH impact on the entire ventral
trisynaptic circuit (Figure 4A, C).
Discussion
Our findings show for the first time that intranasally applied
NPS decreases short- and long-term plasticity at CA3-CA1
synapses in the VH, that microinjections of NPS restricted to
the VH reduce anxiety-like behavior, and that NPS rapidly
weakens neuronal activity flow from the DG to area CA1 in the
VH.
This study uncovers a novel NPS mechanism of action by
showing that NPS, via NPSR, induces a rapid decrease (within
5 min) in neuronal activity flow from the DG to the CA1 region of
the VH (Figure 4). This observation is in line with our previous
finding that intranasally and ICV applied Cy3-NPS accumulates
inter alia in principal neurons of these hippocampal subfields [5].
Recently, using an identical approach, we demonstrated anxio-
genic corticotropin-releasing factor (CRF) [35], [36] to enhance
neuronal activity flow from the DG to the CA1 region [29], [30].
The opposite influences of anxiogenic CRF and anxiolytic NPS on
activity propagation in the above mentioned hippocampal
subfields warrant the speculation that modulation of neuronal
activity flow in the VH might play a principal role in regulating
anxiety-related behavior in rodents and, as the anatomy of the
hippocampus is highly conserved across mammals [37], possibly
also in humans. This speculation is supported by a study which,
also employing a VSDI paradigm, demonstrated that alterations in
the strength of evoked activity propagation within the DG relative
Figure 2. Cy3-NPS is locally restricted to the site of injection
into area CA1 of the VH. A, Injection site on an anatomical plate [24].
Overlay of DAPI (nuclear staining, blue) and Cy3-NPS (red) signals.
Arrow indicates the injection site in the brain section. B, Anatomical
plate showing the lateral (LA) and basolateral (BLA) amygdala, and
overview of the amygdala in a brain section after Cy3-NPS injection
(inset: Cy3 channel only). n = 4. Scale bars, 200 and 20 mm.
doi:10.1371/journal.pone.0060219.g002
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to the hippocampal CA1 output subfield accompany stress-
induced behavioral changes in a rat model of major depression
[33], which, like anxiety diseases, also belongs to the group of
affective disorders.
An NPS-responsive network, encompassing parts of the
amygdala, such as the basolateral (BLA) and lateral (LA) nuclei,
has already been identified by others [7], [38], [39] and intra-
amygdalar injection of NPS was shown to be sufficient to elicit
anxiolytic-like behavior in mice [7], [38]. The NPS-induced
reduction of neuronal activity flow from the DG to area CA1
might possibly contribute to a decrease in the activity of amygdalar
anxiety circuits, since CA1 pyramidal cells of the VH are known to
form excitatory synapses with amygdalar neurons [28], [40].
Additionally, we observed an NPS-mediated long-term (4 h
after intranasal application) decrease in LTP and paired-pulse
facilitation at CA3-CA1 synapses (Figure 1). The latter finding
suggests that NPS activates presynaptic NPSRs at glutamatergic
synapses in the VH, as it has previously been demonstrated to
occur at synapses in the amygdala [7]. The observation of a
decreased magnitude of LTP, however, rather argues for an
additional postsynaptic localization of NPSRs on CA1 pyramidal
neurons [41]. This scenario is also supported by the uptake of
Cy3-NPS into these cells, which we detected both after its direct
administration into the CA1 region (Figure 2) and after intranasal
application [5].
Using two different analysis techniques (i.e. VSDI and fEPSP
recording), we aimed to study different aspects of NPS-induced
modifications of neuronal activity. Both the fast and long-lasting
effects we observed point towards an NPS-mediated decrease in
the overall activity and plasticity in the VH, which could in turn
influence electrical activity within the amygdalar network, thereby
contributing to the net anxiolytic effect of NPS.
To the best of our knowledge, this study is the first to relate
effects of NPS to expression of functional NPSR in the
hippocampus as shown by Cy3-NPS uptake and NPSR-specific
antagonist actions (Figures 2A, 4B and 4C). Indeed, until now,
NPSR expression in the hippocampus had only been described in
the subiculum subfield in rodents [8], [42]. This discrepancy
probably results from different sensitivities of the immunohisto-
chemistry and in situ hybridization techniques used in these studies
and the in vivo Cy3-NPS uptake approach employed here. While it
is widely accepted that the PFC and the amygdala are key players
Figure 3. Microinjections of NPS into the VH reduce anxiety-like behavior in C57BL6/N mice. A, Anatomical plate showing the injection
sites (n = 8 mice per group). B, The distance travelled in the open field was not changed by NPS injection (p = 0.074, t = 1.928, df = 14). C, Anxiety- and
locomotion-related behavior in the dark-light test was not altered by NPS injection (parameters for anxiety-like behavior: % time in light chamber
p = 0.964, t = 0.046, df = 14 and % entries in light chamber p = 0.553, t = 0.608, df = 14; parameter for locomotion: total distance travelled p = 0.54,
t = 0.63, df = 14). D, NPS injections decreased anxiety-related behavior on the EPM (parameter for anxiety-like behavior: % time on open arms
p= 0.042, t = 2.227, df = 14) without affecting locomotion (parameters for locomotion: total distance travelled p = 0.073, t = 1.94, df = 14 and entries in
closed arms p= 0.842, t = 0.203, df = 14).
doi:10.1371/journal.pone.0060219.g003
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in the brain’s anxiety network [18], [43], [44], the role of the VH
in anxiogenesis and anxiolysis is much less established. In humans,
a nonmnemonic role for the hippocampus in emotional processing
has hitherto not clearly emerged [45]. Recently, VH targeting has
been shown to be sufficient for mediating the anxiogenic effect of
CCK8 in rats [15]. Now, to our knowledge, we are the first to
demonstrate that activity modulation in vCA1 is sufficient to
mediate the effects of an exogenously applied anxiolytic agent, i.e.
NPS. Taken together, these observations strongly suggest the VH
as a potential target region for the pharmacotherapy of
pathological anxiety. This hypothesis is in line with reports
showing that lesions or inactivation of the VH result in a reduction
of anxiety-like behavior in rodents [10], [46].
Interestingly, intra-vCA1-injected NPS did not significantly
alter locomotion in any of the three behavioral tests employed
(Figure 3B–D), while, in contrast, former studies reported ICV-
injected NPS to induce hyperlocomotion [47], [48]. This
discrepancy can be explained by the fact that local application
targets only one specific brain structure, whereas ICV injections
will influence several brain regions. Accordingly, intra-amygdalar
injection of NPS also fails to elicit hyperlocomotion [7], [38].
Recent results from studies aiming at elucidating the projection
sites of NPS-producing neurons show mismatches between NPSR
expression and NPS fiber projections inter alia in the hippocampus
[8], [42]. However, these findings do not interfere with our
postulation of the VH as a player in NPS-elicited anxiolysis, since
in our studies we concentrate exclusively on the targets and effects
of exogenously applied NPS. These are of the utmost relevance for a
potential future NPS-based anxiolytic therapy and must not
necessarily overlap with targets and effects of endogenous NPS.
Indeed, different effects of the endogenous NPS system and NPS
treatment are most likely the case, as evidenced by the fact that,
although strong anxiolytic actions of NPS treatment have been
well established, mice lacking NPSR fail to display pathologically
increased anxiety-like behavior [21].
In summary, our study provides the first experimental evidence
for a direct involvement of the VH in NPS-induced anxiolysis,
uncovers a novel mechanism of NPS action by showing NPS to
rapidly weaken the spread of evoked electrical activity in the VH,
and additionally demonstrates that intranasally applied NPS has
the capacity to profoundly modulate glutamatergic synaptic
transmission and plasticity in the VH. Since both the NPS/NPSR
system [49] and the anatomy of the hippocampus [37] are highly
conserved across mammals, it is likely that these findings can be
translated to the situation in humans.
Figure 4. NPS rapidly weakens evoked neuronal activity flow from the DG to area CA1 in hippocampal slices prepared from C57BL/
6N mice. A, (Upper panel) Illustration of the position of the stimulation electrode (Stim) and the three ROIs used for the calculation of neuronal
population activity within the dentate hilus, the CA3 subfield, and area CA1. (Lower panels) Representative filmstrips depicting the propagation of
VSDI signals from the DG to the CA1 region before (‘Baseline’) and after bath application of 1 mM NPS (‘NPS’). Warmer colors represent stronger
neuronal activity. Time specifications are given relative to the electrical stimulation pulse. B, Time course of the experiments depicted for the CA1
output subfield of the VH. NPS (1 mM) decreased FDS peak amplitudes (8465% of baseline, n = 7 slices from 6 mice). This effect was completely
abolished by pretreatment (15 min) of slices with the specific NPSR antagonist (R)-SHA 68 (10 mM) (10163% of baseline, n = 5 slices from 4 mice).
Data were normalized to the mean FDS peak amplitude of the last two acquisitions during baseline recording. C, Quantification of NPS effects on FDS
peak amplitudes in the dentate hilus, the CA3 region, and area CA1. NPS decreased FDS peak amplitudes in the dentate hilus to 8662% (p,0.001,
t = 8.357, df = 6), in CA3 to 9363% (p= 0.037, t = 2.664, df = 6), and in CA1 to 8465% (p= 0.019, t = 3.165, df = 6) of baseline values. These effects were
completely abolished by the NPSR antagonist (R)-SHA 68 (10 mM). Statistical evaluation was performed by comparing the mean FDS peak amplitudes
of the last two acquisitions during baseline recording with the mean FDS peak amplitudes of the last two acquisitions during application of NPS.
doi:10.1371/journal.pone.0060219.g004
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Supporting Information
Figure S1 Procedure of the intranasal application of
NPS. The awake mouse was restrained manually during the
administration procedure in a supine position with the head
immobile at an angle of approximatively 45u to the body.
(TIF)
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